Lanzhou Foci Pharmaceutical Co Ltd (002644) - Total Liabilities
Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) has total liabilities worth CN¥678.01 Million CNY (≈ $99.21 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lanzhou Foci Pharmaceutical Co Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Lanzhou Foci Pharmaceutical Co Ltd to evaluate short-term liquidity relative to the company's equity base.
Lanzhou Foci Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lanzhou Foci Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai HIUV New Materials Co Ltd
SHG:688680
|
China | CN¥1.48 Billion |
|
Flying Technology Co Ltd
SHG:603488
|
China | CN¥353.12 Million |
|
CHC Resources Corp
TW:9930
|
Taiwan | NT$5.29 Billion |
|
Gan Yuan Foods Co Ltd
SHE:002991
|
China | CN¥384.61 Million |
|
Hollyland China Electronics Technology Corp Ltd
SHE:002729
|
China | CN¥113.99 Million |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $16.16 Million |
|
Fineotex Chemical Limited
NSE:FCL
|
India | Rs2.19 Billion |
|
SGL Carbon SE
XETRA:SGL
|
Germany | €701.60 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002644 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lanzhou Foci Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total liabilities of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥654.81 Million ≈ $95.82 Million |
-13.80% |
| 2023-12-31 | CN¥759.67 Million ≈ $111.16 Million |
-10.90% |
| 2022-12-31 | CN¥852.60 Million ≈ $124.76 Million |
+17.67% |
| 2021-12-31 | CN¥724.59 Million ≈ $106.03 Million |
-9.44% |
| 2020-12-31 | CN¥800.08 Million ≈ $117.08 Million |
-10.48% |
| 2019-12-31 | CN¥893.78 Million ≈ $130.79 Million |
-17.52% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.56 Million |
+9.38% |
| 2017-12-31 | CN¥990.68 Million ≈ $144.97 Million |
+32.78% |
| 2016-12-31 | CN¥746.13 Million ≈ $109.18 Million |
+479.45% |
| 2015-12-31 | CN¥128.77 Million ≈ $18.84 Million |
-58.65% |
| 2014-12-31 | CN¥311.40 Million ≈ $45.57 Million |
+55.93% |
| 2013-12-31 | CN¥199.70 Million ≈ $29.22 Million |
+35.50% |
| 2012-12-31 | CN¥147.38 Million ≈ $21.57 Million |
-18.64% |
| 2011-12-31 | CN¥181.14 Million ≈ $26.51 Million |
+39.67% |
| 2010-12-31 | CN¥129.70 Million ≈ $18.98 Million |
-23.30% |
| 2009-12-31 | CN¥169.09 Million ≈ $24.74 Million |
-7.96% |
| 2008-12-31 | CN¥183.70 Million ≈ $26.88 Million |
+11.53% |
| 2007-12-31 | CN¥164.72 Million ≈ $24.10 Million |
-- |
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more